Jul 25, 2022 5:00 pm EDT Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8
Jul 25, 2022 7:00 am EDT DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous Melanoma
Jul 20, 2022 7:00 am EDT Presentation at 2022 AAD Innovation Academy to Showcase the Risk Stratification of DecisionDx®-Melanoma and its Role in the Management of Patients with Cutaneous Melanoma
Jun 23, 2022 5:00 pm EDT Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study Conducted In Collaboration with the Melanoma Research Foundation’s CURE OM Initiative
Jun 22, 2022 7:00 am EDT Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022
Jun 14, 2022 7:00 am EDT Collaborative Study with Melanoma Research Foundation Confirms Patients Diagnosed with Melanoma Desire Testing with DecisionDx®-Melanoma
May 27, 2022 7:00 am EDT Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award
